For instance, in NSCLC with STK11/KEAP1 mutations resistant to PD-(L)1 inhibitors, adding CTLA-4 blockade may restore responses, implying compensatory CTLA-4 upregulation [45]. The gene discussed is KEAP1; the disease is non-small cell lung carcinoma.